July 23 (Reuters) - Drugmaker Biogen Inc reported a 72.4% rise in second-quarter profit on Tuesday, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.
Net income attributable to the company rose to $1.49 billion, or $7.85 per share, in the quarter, from $866.6 million, or $4.18 per share, a year earlier. (https://bit.ly/2LDqLL6)
Total revenue rose to $3.62 billion from $3.36 billion. (Reporting by Saumya Sibi Joseph and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)